Measles virus causes immunogenic cell death in human melanoma

被引：138

作者：

Donnelly, O. G. ^{[1
,2
,4
]}

Errington-Mais, F. ^{[1
]}

Steele, L. ^{[1
]}

Hadac, E. ^{[2
]}

Jennings, V. ^{[1
]}

Scott, K. ^{[1
]}

Peach, H. ^{[4
]}

Phillips, R. M. ^{[3
]}

Bond, J. ^{[1
]}

Pandha, H. ^{[5
]}

Harrington, K. ^{[6
]}

Vile, R. ^{[1
,2
]}

Russell, S. ^{[2
]}

Selby, P. ^{[1
]}

Melcher, A. A. ^{[1
,4
]}

机构：

[1] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England

[2] Mayo Clin, Program Mol Med, Rochester, MN USA

[3] Inst Canc Therapeut, Bradford, W Yorkshire, England

[4] Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England

[5] Univ Surrey, Dept Oncol, Guildford GU2 5XH, Surrey, England

[6] Inst Canc Res, London SW3 6JB, England

来源：

GENE THERAPY | 2013年 / 20卷 / 01期

基金：

英国医学研究理事会;

关键词：

oncolytic; measles; melanoma; immunotherapy; HMGB1; interferon; HUMAN DENDRITIC CELLS; CARCINOEMBRYONIC ANTIGEN; ONCOLYTIC REOVIRUS; INTERFERON-BETA; THERAPY; INNATE; PROTEIN; CANCER; RADIOVIROTHERAPY; VIROTHERAPY;

D O I：

10.1038/gt.2011.205

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host antitumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response. Gene Therapy (2013) 20, 7-15; doi:10.1038/gt.2011.205; published online 15 December 2011

引用

页码：7 / 15

页数：9

共 66 条

[31]

Langfield KK, 2004, MOL THER, V9, pS31

[32] Three-dimensional culture models of normal and malignant breast epithelial cells [J].

Lee, Genee Y. ;

Kenny, Paraic A. ;

Lee, Eva H. ;

Bissell, Mina J. .

NATURE METHODS, 2007, 4 (04) :359-365

[33] Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy [J].

Li, H. ;

Peng, K-W ;

Dingli, D. ;

Kratzke, R. A. ;

Russell, S. J. .

CANCER GENE THERAPY, 2010, 17 (08) :550-558

[34] Prostate-Specific Membrane Antigen Retargeted Measles Virotherapy for the Treatment of Prostate Cancer [J].

Liu, Chunsheng ;

Hasegawa, Kosei ;

Russell, Stephen J. ;

Sadelain, Michel ;

Peng, Kah-Whye .

PROSTATE, 2009, 69 (10) :1128-1141

[35] High-mobility group box 1 protein (HMGB): Nuclear weapon in the immune arsenal [J].

Lotze, MT ;

Tracey, KJ .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :331-342

[36] Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis [J].

Mocellin, Simone ;

Pasquali, Sandro ;

Rossi, Carlo R. ;

Nitti, Donato .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (07) :493-501

[37] Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter [J].

Msaouel, Pavlos ;

Iankov, Ianko D. ;

Allen, Cory ;

Aderca, Ileana ;

Federspiel, Mark J. ;

Tindall, Donald J. ;

Morris, John C. ;

Koutsilieris, Michael ;

Russell, Stephen J. ;

Galanis, Evanthia .

MOLECULAR THERAPY, 2009, 17 (12) :2041-2048

[38]

Msaouel P, 2009, CURR OPIN MOL THER, V11, P43

[39] Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas [J].

Myers, Rae ;

Harvey, Mary ;

Kaufmann, Timothy J. ;

Greiner, Suzanne M. ;

Krempski, James W. ;

Raffel, Corey ;

Shelton, Steven E. ;

Soeffker, Diane ;

Zollman, Paula ;

Federspiel, Mark J. ;

Blanco, Michael ;

Galanis, Evanthia .

HUMAN GENE THERAPY, 2008, 19 (07) :690-698

[40] A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma [J].

O'Day, S. ;

Hodi, F. S. ;

McDermott, D. F. ;

Weber, R. W. ;

Sosman, J. A. ;

Haanen, J. B. ;

Zhu, X. ;

Yellin, M. J. ;

Hoos, A. ;

Urba, W. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

← 1 2 3 4 5 6 7 →